ERBB2 and breast cancer: Therefore, a de-escalating chemotherapy-free phase II trial with a single arm containing dual anti-HER2 blockade with trastuzumab and pertuzumab and the checkpoint inhibitor pembrolizumab is able to evaluate the pCR rate in patients with HER-E BC.